An observational study in Bicuspid Aortic Valve Disease, sponsored by Suzhou Municipal Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2023-11-22.
Sponsored by Suzhou Municipal Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The Chinese Bicuspid Aortic Valve (BAV) Ultrasound imaging cohort study is a Chinese BAV ultrasound imaging cohort study. At present, a retrospective study cohort involving more than 30 hospitals has been established. The prospective multi-center study of BAV is expected to include and follow up 200 outpatients and inpatients with BAV. The clinical, ultrasound imaging and treatment parameters of the patients are collected and the patients are followed up for 2 years. To analyze the prognostic characteristics of BAV patients and establish a Chinese BAV database. The primary endpoint was all-cause death, and the secondary endpoints were heart failure, angina, severe aortic stenosis, severe aortic insufficiency, ascending aortic diameter ≥50mm, and surgery (surgical and interventional). According to the different pathological types of aortic valve in different types of BAV, ultrasound imaging was used to evaluate the different forms of valvular leaflet lesions and prognosis. Finally, it provides a basis for the prognosis, treatment method, treatment timing and treatment plan selection of BAV patients, and lays a foundation for the mechanism study of BAV arterial lesions and the establishment of risk model for the prognosis of BAV patients.
62 studies on the registry are indexed under Bicuspid Aortic Valve Disease; 21 are open to participants now.
This study's planned enrollment of 200 is below the median of 236 across 38 observational studies indexed under Bicuspid Aortic Valve Disease.
Browse Bicuspid Aortic Valve Disease studies →Suzhou Municipal Hospital is the lead sponsor of 9 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Outpatient, inpatient, physical examination or community referral patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diameter of ascending aorta
Diameter of ascending aorta shall be taken using leading edge-to-leading edge convention at end diastole.
Time frame: baseline; once a year; through study completion.
Started Jul 2022 (actual). Primary completion is estimated for Dec 2023, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bicuspid Aortic Valve Disease →
Suzhou Municipal Hospital